Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer
British journal of surgery2016Vol. 103(7), pp. 845–854
Citations Over TimeTop 10% of 2016 papers
Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, K. Kurata, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, S Tanaka, Masahiko Ohsawa, Kosei Hirakawa
Abstract
The CFR may be a useful biomarker to predict treatment response to neoadjuvant therapy in aggressive breast cancer subtypes, such as TNBC and HER2BC.
Related Papers
- → FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction(2020)26 cited
- Neoadjuvant chemotherapy for operable breast cancer.(2002)
- [The Role of Preoperative Chemotherapy Depending on Breast Cancer Subtype].(2016)
- Neoadjuvant Chemotherapy for Breast Cancer and Biological Markers Predicting Curative Effect(2010)
- → PIK3CA mutations and predicting the therapeutic effects of neoadjuvant chemotherapy in primary breast cancer(2020)